Adicet Bio announced that the U.S. Food and Drug Administration, FDA, has cleared the Company’s Investigational New Drug, IND, application to evaluate ADI-270, an armored allogeneic “off-the-shelf” gamma delta chimeric antigen receptor T cell therapy candidate targeting CD70+ cancers, for the treatment of relapsed/refractory renal cell carcinoma, RCC. The Company plans to initiate a Phase 1 clinical trial to assess the safety and anti-tumor activity of ADI-270 in RCC patients in the second half of 2024.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACET:
- Adicet Bio Shareholders Shape Future with Strategic Votes
- Adicet Bio’s ADI-001 Gains FDA Fast Track for Lupus Nephritis
- Adicet Bio receives FDA fast track designation for ADI-001 in Lupus Nephritis
- Adicet Bio reports Q1 EPS (35c), consensus (39c)
- Adicet Bio Shares Insights at Gene and Cell Therapy Meeting